UPB insider transaction filings
Upstream Bio, Inc. — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen UPB transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings by 5 insiders — 5,028 shares, $27,604 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 2,095 shares @ $5.49 ($11,502) by Sutherland Everett Rand, filed 2026-09-17.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Sutherland Everett Rand — Chief Executive Officer, Director | 1 | — | 1 leg · 2,095 sh · $11,502 | — |
| Deykin Aaron — Chief Medical Officer | 1 | — | 1 leg · 895 sh · $4,914 | — |
| GRAY MICHAEL — CFO and COO | 1 | — | 1 leg · 853 sh · $4,683 | — |
| Houghton Adam — Chief Business Officer | 1 | — | 1 leg · 700 sh · $3,843 | — |
| Ambrose Allison — General Counsel | 1 | — | 1 leg · 485 sh · $2,663 | — |
Recent Form 4 filings — Upstream Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Houghton Adam — Chief Business Officer | Sale (S): 700 @ $5.49 | EDGAR |
| 2026-09-17 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Sale (S): 2,095 @ $5.49 | EDGAR |
| 2026-09-17 | 4 | Deykin Aaron — Chief Medical Officer | Sale (S): 895 @ $5.49 | EDGAR |
| 2026-09-17 | 4 | Ambrose Allison — General Counsel | Sale (S): 485 @ $5.49 | EDGAR |
| 2026-09-17 | 4 | GRAY MICHAEL — CFO and COO | Sale (S): 853 @ $5.49 | EDGAR |
| 2026-06-17 | 4 | Houghton Adam — Chief Business Officer | Sale (S): 700 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | Deykin Aaron — Chief Medical Officer | Sale (S): 895 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | Ambrose Allison — General Counsel | Sale (S): 477 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Sale (S): 2,095 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | GRAY MICHAEL — CFO and COO | Sale (S): 853 @ $6.10 | EDGAR |
| 2026-06-11 | 4 | Ruddy Marcella K. — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Fleming Harold Edward — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Chimovits Erez — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Ratcliffe Liam — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Beckman Daniella — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Deykin Aaron — Chief Medical Officer | Sale (S): 894 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | Ambrose Allison — General Counsel | Sale (S): 475 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | Houghton Adam — Chief Business Officer | Sale (S): 699 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Sale (S): 2,093 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | GRAY MICHAEL — CFO and COO | Sale (S): 852 @ $9.29 | EDGAR |
| 2026-01-06 | 4 | Deykin Aaron — Chief Medical Officer | Grant/award (A): 32,000 @ $0 · Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Ambrose Allison — General Counsel | Grant/award (A): 17,000 @ $0 · Grant/award (A): 51,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Houghton Adam — Chief Business Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Grant/award (A): 75,000 @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | GRAY MICHAEL — CFO and COO | Grant/award (A): 30,500 @ $0 · Grant/award (A): 91,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Ruddy Marcella K. — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Fleming Harold Edward — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Chimovits Erez — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Ratcliffe Liam — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Beckman Daniella — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Houghton Adam — Chief Business Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Deykin Aaron — Chief Medical Officer | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Ambrose Allison — General Counsel | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | GRAY MICHAEL — CFO and COO | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | Ambrose Allison — General Counsel | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | Chimovits Erez — Director, 10% owner | Conversion (C): 721,956 · Purchase (P): 165,000 @ $17 · Conversion (C): 2,887,833 · Purchase (P): 660,000 @ $17 · Conversion (C): 524,500 (derivative) · Conversion (C): 2,098,000 (derivative) · +2 more | EDGAR |
| 2024-10-17 | 4 | AI Upstream LLC — 10% owner AI Biotechnology LLC — 10% owner Access Industries Holdings LLC — 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC — 10% owner Blavatnik Len — 10% owner | Purchase (P): 1,175,000 @ $17 · Conversion (C): 3,147,000 · Conversion (C): 1,172,410 · Conversion (C): 3,147,000 (derivative) · Conversion (C): 1,172,410 (derivative) | EDGAR |
| 2024-10-17 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VIII LLC — Director, 10% owner OrbiMed Advisors Israel II Ltd — Director, 10% owner OrbiMed Israel GP II, L.P. — Director, 10% owner | Conversion (C): 721,956 · Purchase (P): 165,000 @ $17 · Conversion (C): 2,887,833 · Purchase (P): 660,000 @ $17 · Conversion (C): 524,500 (derivative) · Conversion (C): 2,098,000 (derivative) · +2 more | EDGAR |
| 2024-10-15 | 4 | Ruddy Marcella K. — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. — 10% owner | Conversion (C): 894,733 · Conversion (C): 852,940 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Fleming Harold Edward — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Chimovits Erez — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Ratcliffe Liam — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Beckman Daniella — Director | Grant/award (A): 34,681 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
Recent 8-K events — Upstream Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=UPB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →